AT515178A5 - Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie - Google Patents
Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie Download PDFInfo
- Publication number
- AT515178A5 AT515178A5 ATA9306/2013A AT93062013A AT515178A5 AT 515178 A5 AT515178 A5 AT 515178A5 AT 93062013 A AT93062013 A AT 93062013A AT 515178 A5 AT515178 A5 AT 515178A5
- Authority
- AT
- Austria
- Prior art keywords
- curcumin
- minimize
- nanocurcumin
- plga
- liposomal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Die vorliegende Erfindung beinhaltet Zusammensetzungen und Verfahren zum Herstellen einer Nanopartikel-Zusammensetzung, welche einen polymeren Kern enthält, der mindestens ein Polymer und mindestens einen Wirkstoff und mindestens eine Schicht mindestens eines Lipids auf der Oberfläche des polymeren Kerns enthält; insbesondere betrifft die Erfindung die Verwendung von Curcumin in einer solchen Lipid-Polymer-Nanopartikel-Formulierung zur Minimierung der QT-Verlängerung in Verbindung mit Curcumin bei der Behandlung von Krebs.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261695827P | 2012-08-31 | 2012-08-31 | |
US14/016,056 US9138411B2 (en) | 2012-08-31 | 2013-08-31 | Curcumin-ER, a liposomal-PLGA sustained release nanocurcumin for minimizing QT prolongation for cancer therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
AT515178A2 AT515178A2 (de) | 2015-06-15 |
AT515178A5 true AT515178A5 (de) | 2015-07-15 |
Family
ID=50184475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ATA9306/2013A AT515178A5 (de) | 2012-08-31 | 2013-08-31 | Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie |
Country Status (5)
Country | Link |
---|---|
US (2) | US9138411B2 (de) |
AT (1) | AT515178A5 (de) |
CA (1) | CA2882978A1 (de) |
DE (1) | DE112013004278T5 (de) |
WO (1) | WO2014036534A1 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9393198B2 (en) | 2010-03-22 | 2016-07-19 | Signpath Pharma Inc. | Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders |
GB2507884B (en) | 2011-06-03 | 2019-10-23 | Signpath Pharma Inc | Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current |
US10238602B2 (en) | 2011-06-03 | 2019-03-26 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies |
US10449193B2 (en) | 2011-06-03 | 2019-10-22 | Signpath Pharma Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies |
US10349884B2 (en) | 2011-06-03 | 2019-07-16 | Sighpath Pharma Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel |
US10117881B2 (en) | 2011-06-03 | 2018-11-06 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies |
CA2933204C (en) | 2013-12-18 | 2020-04-28 | Signpath Pharma, Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel |
EP3151837B1 (de) | 2014-06-03 | 2023-03-15 | Signpath Pharma, Inc. | Schutzwirkung von dmpc, dmpg, dmpc/dmpg, egpg, lysopg und lysopc gegen arzneimittel, die kanalopathien hervorrufen |
RU2571270C1 (ru) * | 2014-07-17 | 2015-12-20 | Открытое Акционерное Общество "Фаберлик" | Липосомальное наносредство на основе продуктов, полученных из корневищ куркумы |
AR101476A1 (es) | 2014-08-07 | 2016-12-21 | Acerta Pharma Bv | Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) |
US10398650B2 (en) | 2015-04-17 | 2019-09-03 | Veliddin Canfeza SEZGIN | Development of curcumin and piperine loaded double-layered biopolymer based nano delivery systems by using electrospray / coating method |
KR102181659B1 (ko) * | 2016-04-27 | 2020-11-24 | 사인패스 파마 인코포레이티드 | 약물 유발된 방실 차단의 방지 |
CN109843331A (zh) * | 2016-10-19 | 2019-06-04 | 萨恩帕斯药物有限公司 | Dmpc、dmpg、dmpc/dmpg、lysopg和lysopc针对引起离子通道病的药物的保护作用 |
ES2960541T3 (es) | 2017-10-19 | 2024-03-05 | Signpath Pharma Inc | Composiciones líquidas para una utilización peroral que comprenden derivados de fosfatidilglicerol y excipientes tixotrópicos para tratar canalopatías cardíacas causadas por agentes farmacológicos |
US10912843B2 (en) * | 2018-04-04 | 2021-02-09 | National Cheng Kung University | Endoplasmic reticulum-targeting nanovehicles and methods for use thereof |
TWI737974B (zh) | 2018-04-09 | 2021-09-01 | 美商標徑製藥公司 | 用於治療增生性失調的劑量方案 |
US20210315830A1 (en) | 2018-08-31 | 2021-10-14 | Council Of Scientific And Industrial Research | A curcumin loaded stabilized polymeric nanoparticles with increased solubility and photo-stability and a green process for the synthesis thereof |
CN109381447B (zh) * | 2018-12-10 | 2021-01-26 | 上海交通大学医学院附属第九人民医院 | 一种载虾青素磷脂纳米粒及其制备方法与应用 |
KR102353979B1 (ko) * | 2020-02-28 | 2022-01-20 | 가천대학교 산학협력단 | 전기분무로 제조된 고분자 리포좀 나노입자 제조방법 |
WO2021176264A1 (en) * | 2020-03-02 | 2021-09-10 | Yogesh Dound | Liposomal compositions and process for preparation thereof |
CN116963724A (zh) * | 2021-03-03 | 2023-10-27 | 萨恩帕斯药物有限公司 | 用于人类恶性胸腔积液的治疗 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020048598A1 (en) * | 1997-06-13 | 2002-04-25 | Navid Malik | Internally supported lipid vesicle systems |
WO2007103435A2 (en) * | 2006-03-06 | 2007-09-13 | The Regents Of The University Of California | Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders |
US20080138400A1 (en) * | 2004-03-05 | 2008-06-12 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of diseases |
US20080253961A1 (en) * | 2007-04-13 | 2008-10-16 | University Of North Texas Health Science Center At Fort Worth | Formulation of Active Agent Loaded Activated PLGA Nanoparticles for Targeted Cancer Nano-Therapeutics |
US20110117186A1 (en) * | 2009-11-19 | 2011-05-19 | Lawrence Helson | Intravenous infusion of curcumin and a calcium channel blocker |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023087A (en) | 1986-02-10 | 1991-06-11 | Liposome Technology, Inc. | Efficient method for preparation of prolonged release liposome-based drug delivery system |
US4812312A (en) | 1987-03-03 | 1989-03-14 | Board Of Regents Of The University Of Texas System | Liposome-incorporated nystatin |
US5679864A (en) | 1995-11-03 | 1997-10-21 | Gene Print Inc. | Process for the synthesis of curcumin-related compounds |
JP3272256B2 (ja) | 1997-01-17 | 2002-04-08 | 丸善製薬株式会社 | クルクミノイドの安定化法および安定化クルクミノイド組成物 |
US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US20010051184A1 (en) | 1999-05-20 | 2001-12-13 | Madalene C.Y. Heng | Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases |
EP1324780A4 (de) | 2000-09-06 | 2005-06-22 | Univ Johns Hopkins | Methoden zur behandlung von herzarrhythmie |
US7060733B2 (en) | 2002-08-15 | 2006-06-13 | The Regents Of The University Of California | Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species |
EG23547A (en) | 2002-11-25 | 2006-05-10 | Mallah Ahmed Ibrahim Mohame El | Preparation of a topical pharmaceutical preparation of curcumin alone or a combination of circumin plus capsaicin as an effective remedy for treatmentof peripheral neuropathies |
US7968115B2 (en) | 2004-03-05 | 2011-06-28 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of cancer |
WO2004080396A2 (en) | 2003-03-07 | 2004-09-23 | The University Of Texas Md Anderson Cancer Center | Liposomal curcumin for treatment of cancer |
WO2005018635A2 (en) | 2003-08-07 | 2005-03-03 | Cardiome Pharma Corp. | Ion channel modulating activity i |
CA2536738A1 (en) | 2003-08-26 | 2005-03-10 | Research Development Foundation | Aerosol delivery of curcumin |
US7067159B2 (en) | 2003-12-05 | 2006-06-27 | New Chapter, Inc. | Methods for treating prostate cancer with herbal compositions |
JP2007526322A (ja) | 2004-03-02 | 2007-09-13 | マサチューセッツ インスティテュート オブ テクノロジー | ナノセル薬物送達系 |
US20080103213A1 (en) | 2004-03-05 | 2008-05-01 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of neurofibromatosis |
US20050233970A1 (en) | 2004-03-23 | 2005-10-20 | Praecis Pharmaceuticals, Inc. | Methods for treating long QT syndrome |
CA2572865C (en) | 2004-07-09 | 2017-07-25 | Robert Sabin | Compositions and methods of use for treatment of mammalian diseases |
EP1807051A2 (de) | 2004-11-05 | 2007-07-18 | Inex Pharmaceuticals Corporation | Zusammensetzungen und verfahren zur stabilisierung liposomer arzneimittelformulierungen |
US20090143433A1 (en) | 2004-12-01 | 2009-06-04 | Curt Hendrix | Cocktail for modulation of alzheimer's disease |
ITMI20042353A1 (it) | 2004-12-10 | 2005-03-10 | Uni Degli Studi Di Modena E Re | Peptidi per la veicolazione di farmaci |
US8202839B1 (en) | 2005-01-04 | 2012-06-19 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
PT1890546T (pt) | 2005-05-30 | 2019-01-23 | Antony Benny | Método para melhorar a biodisponibilidade da curcumina |
WO2007006028A1 (en) | 2005-06-30 | 2007-01-11 | Solutia Inc. | Impact resistant, direct contact plasma display panel filters |
EP2037762A4 (de) | 2006-06-05 | 2009-07-08 | Darrick S H L Kim | Verfahren zur herstellung von reinem curcumin |
US7507864B2 (en) | 2006-08-01 | 2009-03-24 | Salisbury University | Method for the synthesis of curcumin analogues |
US20080075671A1 (en) | 2006-09-22 | 2008-03-27 | Di Mauro Thomas M | Intranasally administering curcumin to the brain to treat alzheimer's disease |
US7593764B2 (en) | 2006-10-03 | 2009-09-22 | General Electric Company | System and method of serial comparison for detection of long QT syndrome (LQTS) |
WO2008073558A2 (en) | 2006-10-05 | 2008-06-19 | The Johns Hopkins University | Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles |
EP2076129B1 (de) | 2006-10-12 | 2016-05-04 | Research Foundation Of The City University Of New York | Neuartiges curcumin dimer |
JP2010505883A (ja) | 2006-10-12 | 2010-02-25 | ザ ユニバーシティー オブ クイーンズランド | 免疫応答を調節するための組成物および方法 |
US20100240581A1 (en) | 2006-11-13 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | Selective proteasome inhibitors for treating diabetes |
US7871609B2 (en) | 2007-03-02 | 2011-01-18 | Sam Ziff | Supplements for pain management |
US20080255464A1 (en) | 2007-04-10 | 2008-10-16 | Vincent G Michael | System and method for diagnosing and treating long qt syndrome |
JP2011500569A (ja) | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
US20090246770A1 (en) | 2007-11-01 | 2009-10-01 | Andrew Levy | Glycemic control for reduction of cardiovascular disease risk in diabetic patients expressing haptoglobin 2-2 |
US8062663B2 (en) | 2008-05-23 | 2011-11-22 | National Health Research Instittues | Methods and compostions for enhancing transdermal drug delivery |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
WO2010009186A1 (en) | 2008-07-15 | 2010-01-21 | The Board Of Trustees Of The University Of Illinois | Liposome formulation having hydrophilic and hydrophobic pharmaceutical compounds co-encapsulated therein |
US20100179103A1 (en) | 2008-07-21 | 2010-07-15 | Ketan Desai | Curcumin cyclodextrin combination for preventing or treating various diseases |
US20120003177A1 (en) | 2008-09-17 | 2012-01-05 | Youqing Shen | Curcumin-containing polymers and water-soluble curcumin derivatives as prodrugs of prodrug carriers |
US20100093873A1 (en) | 2008-10-02 | 2010-04-15 | Goldfischer Sidney L | Methods of improving therapy of perfluorocarbons (PFC) |
CN102217230B (zh) | 2008-11-19 | 2015-02-25 | 爱立信(中国)通信有限公司 | 开通方法和系统 |
US20120021036A1 (en) | 2009-01-15 | 2012-01-26 | The Regents Of The University Of California | Composite nanostructures and methods for making and using them |
US7723515B1 (en) | 2009-01-26 | 2010-05-25 | Codman & Shurtleff, Inc. | Methylene blue—curcumin analog for the treatment of alzheimer's disease |
US20100239552A1 (en) | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Combination Therapies for Treating Metabolic Disorders |
WO2011001351A1 (en) | 2009-07-01 | 2011-01-06 | Koninklijke Philips Electronics N. V. | Stimuli-responsive carriers for mpi-guided drug delivery |
US9393198B2 (en) | 2010-03-22 | 2016-07-19 | Signpath Pharma Inc. | Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders |
US20120058208A1 (en) | 2010-09-04 | 2012-03-08 | Synthite Industries Ltd. | Synergistic Composition for Enhancing Bioavailability of Curcumin |
US9447027B2 (en) | 2010-10-22 | 2016-09-20 | The General Hospital Corporation | Treating long QT syndrome |
WO2012125830A2 (en) | 2011-03-16 | 2012-09-20 | Signpath Pharma, Inc. | Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control |
GB2507884B (en) | 2011-06-03 | 2019-10-23 | Signpath Pharma Inc | Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current |
US9170257B2 (en) | 2012-06-14 | 2015-10-27 | Signpath Pharma Inc. | Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin |
-
2013
- 2013-08-31 US US14/016,056 patent/US9138411B2/en active Active
- 2013-08-31 WO PCT/US2013/057744 patent/WO2014036534A1/en active Application Filing
- 2013-08-31 DE DE112013004278.9T patent/DE112013004278T5/de not_active Withdrawn
- 2013-08-31 CA CA2882978A patent/CA2882978A1/en not_active Abandoned
- 2013-08-31 AT ATA9306/2013A patent/AT515178A5/de not_active Application Discontinuation
-
2015
- 2015-05-29 US US14/725,624 patent/US20150258026A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020048598A1 (en) * | 1997-06-13 | 2002-04-25 | Navid Malik | Internally supported lipid vesicle systems |
US20080138400A1 (en) * | 2004-03-05 | 2008-06-12 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of diseases |
WO2007103435A2 (en) * | 2006-03-06 | 2007-09-13 | The Regents Of The University Of California | Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders |
US20080253961A1 (en) * | 2007-04-13 | 2008-10-16 | University Of North Texas Health Science Center At Fort Worth | Formulation of Active Agent Loaded Activated PLGA Nanoparticles for Targeted Cancer Nano-Therapeutics |
US20110117186A1 (en) * | 2009-11-19 | 2011-05-19 | Lawrence Helson | Intravenous infusion of curcumin and a calcium channel blocker |
Also Published As
Publication number | Publication date |
---|---|
WO2014036534A1 (en) | 2014-03-06 |
DE112013004278T5 (de) | 2015-05-21 |
AT515178A2 (de) | 2015-06-15 |
US9138411B2 (en) | 2015-09-22 |
US20150258026A1 (en) | 2015-09-17 |
CA2882978A1 (en) | 2014-03-06 |
US20140065061A1 (en) | 2014-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AT515178A5 (de) | Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie | |
PH12015501486B1 (en) | Nanoparticle compositions of albumin and paclitaxel | |
CL2016002308A1 (es) | Nanopartículas que comprenden un ácido hidrofóbico, un copolímero de dibloque pla-peg o plga-peg, y 1 -4- 4-dimetilamino piperidin-1-il carbonilfenil-3-4-4,6-dimorfolin-4-il-1,3,5-triazin-2-ilfenilurea composición farmacética proceso de preparación y uso para tratar cáncer | |
JP2016504362A5 (de) | ||
BR112017016093A2 (pt) | composição sólida, curativo de ferida, e, método de fabricação de uma composição | |
BR112015023629A2 (pt) | formulação de acetato de abiraterona | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
BR112016011065A8 (pt) | composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia | |
EP3424907A3 (de) | Verbindungen und organische elektronische vorrichtungen | |
JP2012140433A5 (de) | ||
WO2015077503A8 (en) | Autotaxin inhibitor compounds | |
HN2011002406A (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
PE20141792A1 (es) | Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona | |
WO2011099832A3 (en) | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same | |
BR112017003346B8 (pt) | Derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
BR112015006017A2 (pt) | estabilização de sistemas de cápsulas em produtos de lavagem e outros produtos de limpeza | |
WO2016059020A3 (en) | Polymer micelles containing nanoparticles in non-aqueous solution, methods for their preparation and use | |
WO2013087734A3 (en) | Functionalised silicon nanoparticles | |
NZ702087A (en) | Pharmaceutical compositions and treatment of mastitis | |
WO2017017063A3 (en) | Nanoparticle-based liver-targeting therapy and imaging | |
CO2017012573A2 (es) | Formación de nanopartículas de ciclosporina a/ciclodextrina | |
WO2016142708A3 (en) | Pharmaceutical composition | |
MX2017010422A (es) | Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes. | |
DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
EP2698142A3 (de) | Zahnfüllungsmaterialien und Zahnlacke zur Hemmung der Biofilmbildung von Streptococcus mutans und deren Herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REJ | Rejection |
Effective date: 20180215 |